TRANSIENT OLIGOCLONAL BANDS AND COMPLETE BRAIN LESION RESOLUTION IN PEDIATRIC MOGAD INITIALLY DIAGNOSED AS MULTIPLE SCLEROSIS: A 30-MONTH CASE REPORT
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6478Keywords:
MOGAD; Pediatric Demyelination; Misdiagnosis; Multiple Sclerosis; Oligoclonal Bands; Intravenous ImmunoglobulinAbstract
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can overlap clinically and radiologically with pediatric-onset multiple sclerosis (MS). Transient cerebrospinal fluid (CSF) oligoclonal bands (OCBs), which may substitute for dissemination in time under the 2017 McDonald criteria, can contribute to diagnostic misclassification when interpreted without disease-specific serology.
Case Presentation: A 15-year-old girl presented with binocular diplopia, dysarthria, and balance impairment. Brain MRI showed multiple non-enhancing lesions, and spinal MRI demonstrated multilevel intramedullary lesions. CSF was acellular with CSF-restricted OCBs. The findings were interpreted as fulfilling the 2017 McDonald criteria, and interferon beta-1b was initiated. At month 9, serum MOG-IgG was positive by cell-based assay (titer 1:100), while AQP4-IgG was negative. At month 14, the cerebral lesions had resolved completely, repeat CSF OCB testing was negative, and MOG-IgG remained positive. The diagnosis was reclassified as MOGAD, interferon beta-1b was discontinued, and maintenance intravenous immunoglobulin was initiated at month 18. At month 30, the patient remained clinically stable with an EDSS score of 0; the last documented MOG-IgG result at month 25 remained positive.
Discussion: The longitudinal combination of transient OCB positivity and complete radiological resolution of extensive brain lesions prompted diagnostic reassessment. The case illustrates why formal fulfillment of MS criteria should be integrated with the clinical phenotype, disease-specific antibody testing, and serial MRI findings in pediatric demyelinating disease.
Conclusions: Early serum MOG-IgG testing should be considered in children with a first demyelinating event, particularly when the phenotype or subsequent MRI evolution is atypical for MS. CSF OCB positivity should not be regarded as disease-specific evidence of MS in isolation.
References
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., et al. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology, 22(3), 268–282. https://doi.org/10.1016/S1474-4422(22)00431-8
Reindl, M., & Waters, P. (2019). Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Reviews Neurology, 15(2), 89–102. https://doi.org/10.1038/s41582-018-0112-x
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A. K., Aktas, O., Alexopoulos, H., et al. (2021). Myelin-oligodendrocyte glycoprotein antibody-associated disease. The Lancet Neurology, 20(9), 762–772. https://doi.org/10.1016/S1474-4422(21)00218-0
Armangue, T., Olive-Cirera, G., Martinez-Hernandez, E., Sepulveda, M., Ruiz-Garcia, R., Andres-Benito, P., et al. (2020). Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: A multicentre observational study. The Lancet Neurology, 19(3), 234–246. https://doi.org/10.1016/S1474-4422(19)30488-0
Fadda, G., Armangue, T., Hacohen, Y., Chitnis, T., & Bhatt, P. (2021). Paediatric multiple sclerosis and antibody-associated demyelination: Clinical, imaging, and biological considerations for diagnosis and care. The Lancet Neurology, 20(2), 136–149. https://doi.org/10.1016/S1474-4422(20)30432-4
Bruijstens, A. L., Lechner, C., Flet-Berliac, L., Deiva, K., Neuteboom, R. F., Hemingway, C., et al. (2020). E.U. paediatric MOG consortium consensus: Part 1—Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated diseases. European Journal of Paediatric Neurology, 29, 2–13. https://doi.org/10.1016/j.ejpn.2020.10.006
Kim, H. J., Paul, F., Lana-Peixoto, M. A., Tenembaum, S., Asgari, N., Palace, J., et al. (2015). MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology, 84(11), 1165–1173. https://doi.org/10.1212/WNL.0000000000001367
Montalban, X., Lebrun-Frénay, C., Oh, J., Arrambide, G., Moccia, M., Amato, M. P., et al. (2025). Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. The Lancet Neurology, 24(10), 850–865. https://doi.org/10.1016/S1474-4422(25)00270-4
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Ciron, J., et al. (2018). Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology, 90(21), e1858–e1869. https://doi.org/10.1212/WNL.0000000000005560
Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., et al. (2016). MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 13, 280. https://doi.org/10.1186/s12974-016-0718-0
Hacohen, Y., Wong, Y. Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., et al. (2018). Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurology, 75(4), 478–487. https://doi.org/10.1001/jamaneurol.2017.4601
Whittam, D. H., Cobo-Calvo, A., Lopez-Chiriboga, A. S., Pardo, S., Kim, M., Hor, J. Y., et al. (2020). Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 44, 102251. https://doi.org/10.1016/j.msard.2020.102251
Fadda, G., Banwell, B., Waters, P., Hannan, S., Guo, R., Gholipour, T., et al. (2021). Silent new brain MRI lesions in children with MOG-antibody associated disease. Annals of Neurology, 89(2), 408–413. https://doi.org/10.1002/ana.25957
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., et al. (2017). Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain, 140(12), 3128–3138. https://doi.org/10.1093/brain/awx276
Reindl, M., Schanda, K., Woodhall, M., Tea, F., Ramanathan, S., Sagen, J., et al. (2020). International multicenter examination of MOG antibody assays. Neurology: Neuroimmunology & Neuroinflammation, 7(2), e674. https://doi.org/10.1212/NXI.0000000000000674
Vilaseca, A., Bilodeau, P. A., Gakis, G., Savransky, A., Oliveira, J. M. F., Nguyen, L., et al. (2026). Interleukin 6 receptor blockade for relapse prevention in myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurology. Advance online publication. https://doi.org/10.1001/jamaneurol.2026.2220
Ramírez, E., Romero-Garrido, J. A., López-Granados, E., Borobia, A. M., Pérez, T., Medrano, N., et al. (2014). Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: Results from a retrospective cohort study. Thrombosis Research, 133(6), 1045–1051. https://doi.org/10.1016/j.thromres.2014.03.046
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Bartosz Wójtowicz, Oliwia Żmuda, Szymon Skrzypek, Natalia Skórka, Karolina Skórka, Ilona Owsiana, Magdalena Chrościńska- Krawczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
